Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
731 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01468688 | A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT01735968 | A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT02703571 | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | terminated | Phase 1 | 95 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT00788931 | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT03333694 | Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | terminated | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 11, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT02626234 | A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT01155453 | A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 113 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01285466 | A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | completed | Phase 1 | 110 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01928459 | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01275209 | Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma(LIFT) | completed | Phase 1 | 1 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 8, 2020 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03692429 | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells(alloSHRINK) | recruiting | Phase 1 | 49 | Celyad Oncology SAINDUSTRY | 2 | Nov 20, 2020 | clinicaltrials |
| NCT03704467 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | completed | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Nov 13, 2020 | clinicaltrials |
| NCT03183544 | Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit(PSMA) | completed | Phase 1 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT03553108 | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.(IVIVC) | completed | Phase 1 | 18 | AstraZenecaINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT03883776 | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors | completed | Phase 1 | 12 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03539484 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | terminated | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 4 | Sep 3, 2020 | clinicaltrials |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | terminated | Phase 1 / Phase 2 | 25 | The Lymphoma Academic Research OrganisationOTHER | 2 | Sep 2, 2020 | clinicaltrials |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 221 | Hoffmann-La RocheINDUSTRY | 4 | Aug 27, 2020 | clinicaltrials |
| NCT01296932 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 1 | 37 | Boehringer IngelheimINDUSTRY | 3 | Aug 20, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT02824042 | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | completed | Phase 1 | 63 | BayerINDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT02411591 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 66 | Eli Lilly and CompanyINDUSTRY | 3 | Jul 9, 2020 | clinicaltrials |
| NCT03310008 | Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases(SHRINK) | unknown | Phase 1 | 36 | Celyad Oncology SAINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03138083 | OMO-1 in Solid Malignancies | terminated | Phase 1 / Phase 2 | 40 | Octimet Oncology N.V.INDUSTRY | 5 | Jun 11, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT04167696 | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02(CYCLE-1) | recruiting | Phase 1 | 27 | Celyad Oncology SAINDUSTRY | 2 | Jun 9, 2020 | clinicaltrials |
| NCT03955939 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | completed | Phase 1 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 1, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT00983619 | A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies | completed | Phase 1 / Phase 2 | 136 | MedImmune LLCINDUSTRY | 5 | May 13, 2020 | clinicaltrials |
| NCT02316197 | Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | completed | Phase 1 | 31 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Apr 28, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02219724 | A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 174 | Genentech, Inc.INDUSTRY | 6 | Feb 5, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials